Drug Profile
Research programme: cancer therapeutics - Kainos Medicine
Alternative Names: Cytotoxic nucleic acid derivatives; KM101; KM301; KM601Latest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator Kainos Medicines
- Developer Kainos Medicines; Undisclosed Company
- Class Antineoplastics; Enzymes; Nucleosides; Nucleotides; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; DNA methylation inhibitors; Enhancer of zeste homolog 2 protein inhibitors; Immunomodulators; Nucleic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Cancer; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 07 Jul 2022 Cancer therapeutics is still in Early research for Breast cancer, Haematological malignancies, Leukaemia, Myelodysplastic syndromes, Myeloid leukaemia, Non-Hodgkin's lymphoma, Solid tumours (Kainos Medicine pipeline, July 2022)
- 07 Jul 2022 Early research in Cancer in South Korea (unspecified route) (Kainos Medicines pipeline, July 2022)
- 28 May 2022 No recent reports of development identified for research development in Haematological-malignancies in South Korea (PO)